CAR T-cell therapy is a type of immunotherapy that uses altered immune cells (T-cells) to find & attack tumor cells. During the therapy, a patient’s T cells are extracted & genetically altered to express a CAR (Chimeric Antigen Receptor) that recognizes a protein on the surface of cancer cells. The modified T-cells are then multiplied & infused back into the patient, where they identify & destroy tumor cells and might remain in the body for months after the infusion.
The therapy can result in severe side effects, which is why patients stay in the hospital for a week or two for monitoring. Its efficacy in the treatment of hematologic malignancies has been well-proved, and there are numerous ongoing research activities to identify if it helps treat solid tumors.
The Global Chimeric Antigen Receptor (CAR) T-cell Therapy Market is projected to register exponential CAGR during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the burgeoning adoption of CAR T-cell therapy to address the rising patient pool for blood cancers, including lymphomas, certain forms of leukemia, & also multiple myeloma, on account of the mounting awareness regarding its benefits over traditional treatments.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: The US, Canada, Mexico|
|Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe|
|Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific|
|South America: Brazil, Rest of Latin America|
|Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa|
|Key Companies Profiled||
Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sorrento Therapeutics, Inc., Others
|Unit Denominations||USD Million/Billion|
Various ongoing R&D activities in the life science & biotechnology sectors across numerous countries for blood cancer treatment using chimeric antigen receptors to evaluate CAR T-cell therapy's effectiveness, safety, mechanism of drug action, and adherence in patients with lymphoma & leukemia are also augmenting the overall growth of the global market.
The approvals of Kymriah & Yescarta earlier in 2017, their expansion across Japan & Europe during 2018-19, and their steadily growing global sales have proved to be a milestone for the Global CAR T-cell Therapy Market. Since then, there have been rapid & notable developments in the field as researchers are tweaking the efficacy & safety of CAR T-cells using novel approaches.
Despite the immense success of CAR T-cell therapy in treating blood cancers, there's still a major missing to its full potential since its application is limited only to certain liquid tumors in relapsed & refractory stages. Challenges like complex manufacturing & supply chain, high costs, and delayed preapproval reimbursement for patients are affecting its commercialization and, in turn, hampering the market growth.
However, with the optimization of autologous CAR T-cells for liquid malignancies, expansion of healthcare facilities, and fast & innovative developments of effective biomarkers to treat solid tumors, the Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market could witness remunerative prospects over the coming years.